AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26250359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4113
Study 23430759 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 0
Study 23430759 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of genotypes associated with an anti-inflammatory profile
Number of subjects: 0
Study 21610263 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle technique (DB group)
Number of subjects: 153
Study 21610263 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle technique (SB group)
Number of subjects: 153
Study 21610263 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 153
Study 18094222 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ATRA (2 mg/kg/day)
Number of subjects: 116
Study 18094222 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cRA (1 mg/kg/day)
Number of subjects: 116
Study 18094222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 18094222 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ATRA (1 mg/kg/day)
Number of subjects: 116
Study 17178958 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Povidone-iodine (PVI)
Number of subjects: 517
Study 17178958 — intervention group
Group type: COMPARATOR
Intervention: 0.3% Sodium hypochlorite
Number of subjects: 517
Study 12849825 — intervention group
Group type: EXPERIMENTAL
Intervention: NovaSure endometrial ablation
Number of subjects: 57
Study 12849825 — intervention group
Group type: COMPARATOR
Intervention: Cavaterm endometrial ablation
Number of subjects: 57
Study 10473232 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg p.o. od for 7 days
Number of subjects: 77
Study 10473232 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol 2-3 g p.o. od in four divided doses for 14 days
Number of subjects: 77
Study 8777096 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 54
Study 8777096 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 54
Study 2066449 — intervention group
Group type: EXPERIMENTAL
Intervention: V6+ (chewing gum containing hydrogen peroxide)
Number of subjects: 12
Study 2066449 — intervention group
Group type: COMPARATOR
Intervention: PLAC (V6 placebo gum)
Number of subjects: 12
Study 2066449 — intervention group
Group type: COMPARATOR
Intervention: GB (gum base as negative control)
Number of subjects: 12
Study 7048518 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemo/hormonotherapy
Number of subjects: 406
Study 7048518 — intervention group
Group type: COMPARATOR
Intervention: Hormonal treatment alone with delayed chemotherapy until tumor progression
Number of subjects: 406
Study 7048518 — intervention group
Group type: EXPERIMENTAL
Intervention: More aggressive cytotoxic combinations (LMFP, LMP/FVP, LMFP/ADM)
Number of subjects: 406
Study 7048518 — intervention group
Group type: COMPARATOR
Intervention: Minimal chemotherapy
Number of subjects: 406
Study 31719080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant+ app and usual care
Number of subjects: 238
Study 31719080 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 238
Study 31719080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant+ app
Number of subjects: 238
Study 30220262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovaprim™ (0.5 ml/kg)
Number of subjects: 12
Study 30220262 — intervention group
Group type: EXPERIMENTAL
Intervention: Carp pituitary extract (CPE; 2.0 mg/kg)
Number of subjects: 12
Study 30220262 — intervention group
Group type: COMPARATOR
Intervention: NaCl solution 0.9% (control group; 0.5 ml/kg)
Number of subjects: 12
Study 27487909 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral TAP block with 20 ml of ropivacaine
Number of subjects: 80
Study 27487909 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 80
Study 24490628 — intervention group
Group type: EXPERIMENTAL
Intervention: VL + local anesthesia without analgesics
Number of subjects: 884
Study 24490628 — intervention group
Group type: COMPARATOR
Intervention: VL + local anesthesia + analgesics
Number of subjects: 884
Study 21425346 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence group therapy (three sessions per week for 24 weeks)
Number of subjects: 129
Study 21425346 — intervention group
Group type: COMPARATOR
Intervention: Weekly individual supportive interviews (control group)
Number of subjects: 129
Study 21425346 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 129
Study 20336063 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month extended transdermal nicotine therapy
Number of subjects: 471
Study 20336063 — intervention group
Group type: COMPARATOR
Intervention: 8-week standard transdermal nicotine therapy
Number of subjects: 471
Study 16934840 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 40mg/day
Number of subjects: 1619
Study 16934840 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg/day
Number of subjects: 1619
Study 16934840 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 80mg/day
Number of subjects: 1619
Study 16934840 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120mg/day
Number of subjects: 1619
Study 16934840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1619
Study 11315126 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia + L-arginine
Number of subjects: 28
Study 11315126 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 28
Study 9308941 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia and radiation
Number of subjects: 120
Study 8340045 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (NLX, 2mg, IV)
Number of subjects: 16
Study 8340045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P, Physiologic saline, 10ml)
Number of subjects: 16
Study 2947447 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of oral nicorandil
Number of subjects: 11
Study 2947447 — intervention group
Group type: COMPARATOR
Intervention: sublingual nitroglycerin
Number of subjects: 11
Study 29698966 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamine oxidase (DAO) supplementation, 1 capsule b.i.d., 15 min before a meal for 30 days
Number of subjects: 22
Study 29698966 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamine oxidase (DAO) supplementation
Number of subjects: 22
Study 29698966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 26364551 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2014 (50 mg twice daily)
Number of subjects: 49
Study 26364551 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (10 mg once daily)
Number of subjects: 49
Study 26364551 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2014
Number of subjects: 49
Study 26364551 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 49
Study 25706861 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR) - 6.5 hours in bed
Number of subjects: 31
Study 25706861 — intervention group
Group type: COMPARATOR
Intervention: Healthy Sleep (HS) - 10 hours in bed
Number of subjects: 31
Study 25706861 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR)
Number of subjects: 31
Study 23097413 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma gel (PRPG)
Number of subjects: 50
Study 23097413 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 20942866 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent arm (Arm C) - R-CHOP: 6 R treatments (375 mg/m²) 2 days prior to each cycle of CHOP
Number of subjects: 67
Study 20942866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential arm (Arm S) - R-CHOP: 6 weekly R treatments (375 mg/m²) following six cycles of CHOP
Number of subjects: 67
Study 20942866 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall for all assessable patients
Number of subjects: 67
Study 18257603 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of donepezil (15 mg/day for weeks 1-12; 20 mg/day for weeks 13-24)
Number of subjects: 31
Study 18257603 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of donepezil (10 mg/day plus placebo 5 mg/day for weeks 1-12; 10 mg/day plus placebo 10 mg/day for weeks 13-24)
Number of subjects: 31
Study 18257603 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of donepezil
Number of subjects: 31
Study 18257603 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of donepezil
Number of subjects: 31
Study 16773586 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern visual evoked potentials (PVEPs)
Number of subjects: 15
Study 12744985 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive medicine curriculum (case-based approach)
Number of subjects: 0
Study 11051124 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 102
Study 11051124 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin
Number of subjects: 102
Study 11051124 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (per protocol)
Number of subjects: 102
Study 11051124 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin (per protocol)
Number of subjects: 102
Study 11051124 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin (perimetry results)
Number of subjects: 102
Study 8791949 — intervention group
Group type: EXPERIMENTAL
Intervention: dirithromycin 500 mg q.d.s. alone
Number of subjects: 32
Study 8791949 — intervention group
Group type: EXPERIMENTAL
Intervention: dirithromycin 500 mg q.d.s. plus omeprazole 40 mg q.d.s.
Number of subjects: 32
Study 8791949 — intervention group
Group type: EXPERIMENTAL
Intervention: dirithromycin 500 mg q.d.s. plus metronidazole 500 mg t.d.s.
Number of subjects: 32
Study 8791949 — intervention group
Group type: COMPARATOR
Intervention: omeprazole 500 mg q.d.s. plus amoxycillin 20 mg b.d.
Number of subjects: 32
Study 8791949 — intervention group
Group type: EXPERIMENTAL
Intervention: dirithromycin alone or combined with omeprazole
Number of subjects: 32
Study 1611329 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 128
Study 1611329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (24 g/day)
Number of subjects: 128
Study 30558079 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosinji granule (2.5 g, 1.523 g of Bosinji extract)
Number of subjects: 74
Study 30558079 — intervention group
Group type: COMPARATOR
Intervention: Loxonin tablet (60 mg of loxoprofen)
Number of subjects: 74
Study 27138023 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (10, 75, 250, or 750mg)
Number of subjects: 35
Study 27138023 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (75-750mg)
Number of subjects: 35
Study 27138023 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 35
Study 25154469 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous e-learning modules
Number of subjects: 256
Study 25154469 — intervention group
Group type: COMPARATOR
Intervention: Current education standards (Control)
Number of subjects: 256
Study 22856518 — intervention group
Group type: EXPERIMENTAL
Intervention: GG genotype for rs2383206
Number of subjects: 611
Study 22856518 — intervention group
Group type: COMPARATOR
Intervention: AA and AG genotypes for rs2383206
Number of subjects: 611
Study 22856518 — intervention group
Group type: EXPERIMENTAL
Intervention: rs2383206 genotype
Number of subjects: 611
Study 20566013 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of Urogenital Distress Inventory‐6 (UDI‐6) questionnaire
Number of subjects: 26
Study 20566013 — intervention group
Group type: COMPARATOR
Intervention: Paper version of Urogenital Distress Inventory‐6 (UDI‐6) questionnaire
Number of subjects: 26
Study 20566013 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of Incontinence Impact Questionnaire‐7 (IIQ‐7) questionnaire
Number of subjects: 26
Study 20566013 — intervention group
Group type: COMPARATOR
Intervention: Paper version of Incontinence Impact Questionnaire‐7 (IIQ‐7) questionnaire
Number of subjects: 26
Study 18094309 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mmol/kg gadofosveset
Number of subjects: 185
Study 18094309 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mmol/kg gadofosveset
Number of subjects: 185
Study 18094309 — intervention group
Group type: COMPARATOR
Intervention: No contrast agent
Number of subjects: 185
Study 17274520 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose sublingual specific immunotherapy with a 6-grass-pollen mixture
Number of subjects: 0
Study 17274520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12730632 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostar XL device
Number of subjects: 109
Study 12730632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloride lidocaine containing 1% epinephrine as local anesthesia
Number of subjects: 109
Study 10909169 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab 15 mg/kg
Number of subjects: 1502
Study 10909169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1502
Study 10323119 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 40
Study 10323119 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 1728190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (15 sessions)
Number of subjects: 71
Study 1728190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (medication withdrawn at 16 or 24 weeks)
Number of subjects: 71
Study 1728190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (24-week duration)
Number of subjects: 71
Study 1728190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 71
Study 1728190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy
Number of subjects: 71
Study 1728190 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (16 weeks)
Number of subjects: 71
Study 6332274 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypassed arteries with minimal atherosclerosis
Number of subjects: 85
Study 6332274 — intervention group
Group type: COMPARATOR
Intervention: Non-bypassed arteries with minimal atherosclerosis
Number of subjects: 85
Study 30978683 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 10 mg/kg
Number of subjects: 233
Study 30978683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 233
Study 29505147 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral Protein Calculator (PPC)
Number of subjects: 42
Study 29505147 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 42
Study 26542272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Number of subjects: 96
Study 26542272 — intervention group
Group type: COMPARATOR
Intervention: Armodafinil
Number of subjects: 96
Study 24281905 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 FA‐enriched oral nutritional supplement (Supportan, 200 ml twice daily) providing 2.0 g EPA and 1.0 g DHA per day
Number of subjects: 148
Study 24281905 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 FA‐enriched oral nutritional supplement
Number of subjects: 148
Study 24281905 — intervention group
Group type: COMPARATOR
Intervention: Standard isocaloric and isonitrogenous ONS
Number of subjects: 148
Study 22128200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 0.5 mg daily
Number of subjects: 102
Study 22128200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 1 mg daily
Number of subjects: 102
Study 22128200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 2 mg daily
Number of subjects: 102
Study 22128200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 3 mg daily
Number of subjects: 102
Study 19503774 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-assisted stretching program (AA), performed twice weekly for eight weeks
Number of subjects: 17
Study 19503774 — intervention group
Group type: COMPARATOR
Intervention: Control group (limited physical activity classes)
Number of subjects: 17
Study 18385202 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (3 to 9 courses)
Number of subjects: 1475
Study 16105989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 1012
Study 16105989 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents
Number of subjects: 1012
Study 11991371 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet transform of heart rate intervals for automatic AF detection
Number of subjects: 80
Study 9951469 — intervention group
Group type: EXPERIMENTAL
Intervention: Surodex (dexamethasone 60 micrograms) inserted in the anterior chamber of 32 eyes, followed by placebo eyedrops four times a day for 4 weeks.
Number of subjects: 60
Study 9951469 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.1% eyedrops prescribed four times a day for 4 weeks (control group).
Number of subjects: 60
Study 9951469 — intervention group
Group type: EXPERIMENTAL
Intervention: Surodex (dexamethasone 60 micrograms)
Number of subjects: 60
Study 9951469 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.1% eyedrops
Number of subjects: 60
Study 7479200 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 4 g plus tazobactam 500 mg by intravenous intermittent infusion every 8 hours
Number of subjects: 18
Study 2320708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg q8h
Number of subjects: 26
Study 2320708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg q8h
Number of subjects: 26
Study 2320708 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg q12h
Number of subjects: 26
Study 2320708 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 26
Study 7367815 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone sodium
Number of subjects: 54
Study 7367815 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic drug therapy
Number of subjects: 54
Study 7367815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest in hospital
Number of subjects: 54
Study 7367815 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to cease smoking
Number of subjects: 54
Study 7367815 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 54
Study 7367815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcer size
Number of subjects: 54
Study 30419498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (50,000 IU/wk)
Number of subjects: 22
Study 30419498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28132574 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training (RAGT) using Lokomat device
Number of subjects: 38
Study 28132574 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training (Control)
Number of subjects: 38
Study 28132574 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received 30 min of conventional exercise program (CEP)
Number of subjects: 38
Study 28132574 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training (RAGT)
Number of subjects: 38
Study 25967465 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel guide-wire technique
Number of subjects: 50
Study 25967465 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 50
Study 22581193 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional rotator training combined with heavy load eccentric training (TT + ET)
Number of subjects: 61
Study 22581193 — intervention group
Group type: COMPARATOR
Intervention: Traditional rotator cuff training (TT)
Number of subjects: 61
Study 21318559 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 10 ppm
Number of subjects: 15
Study 21318559 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized iloprost at 0.5 µg/kg every 2 hours
Number of subjects: 15
Study 19732457 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 0
Study 19732457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19732457 — intervention group
Group type: COMPARATOR
Intervention: Voglibose
Number of subjects: 0
Study 17355742 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0
Study 17355742 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 15901125 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500-Hz AC
Number of subjects: 23
Study 15901125 — intervention group
Group type: COMPARATOR
Intervention: 3750-Hz AC
Number of subjects: 23
Study 15901125 — intervention group
Group type: COMPARATOR
Intervention: 5000-Hz AC
Number of subjects: 23
Study 11956265 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rIFN alpha-2b
Number of subjects: 642
Study 11956265 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rIFN alpha-2b
Number of subjects: 642
Study 11956265 — intervention group
Group type: COMPARATOR
Intervention: Observation arm
Number of subjects: 642
Study 11956265 — intervention group
Group type: EXPERIMENTAL
Intervention: ECS in lymph nodes
Number of subjects: 642
Study 9838912 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 41
Study 9838912 — intervention group
Group type: COMPARATOR
Intervention: Conventional antiemetics
Number of subjects: 41
Study 8559919 — intervention group
Group type: EXPERIMENTAL
Intervention: Imedeen (food supplement)
Number of subjects: 45
Study 8559919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 2235345 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-30 (30 micrograms injections of Z-100)
Number of subjects: 0
Study 2235345 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-20 (20 micrograms injections of Z-100)
Number of subjects: 0
Study 2235345 — intervention group
Group type: COMPARATOR
Intervention: IN (inosine)
Number of subjects: 0
Study 427822 — intervention group
Group type: EXPERIMENTAL
Intervention: iv melphalan
Number of subjects: 425